-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Efficacy was assessed in the FIGHT-203 study (NCT03011372), a multicenter, open-label, single-arm trial that enrolled 28 patients with relapsed or refractory MLN with FGFR1 rearrangement
Efficacy was determined based on complete remission (CR) rates
The most common (≥20%) adverse reactions were hyperphosphatemia, nail toxicity, alopecia, stomatitis, diarrhea, dry eye, fatigue, rash, abdominal pain, anemia, constipation, dry mouth, epistaxis, serous retinal detachment , Pain in extremities, loss of appetite, dry skin, indigestion, back pain, nausea, blurred vision, peripheral edema, and dizziness
The recommended dose of pemitinib is 13.
Reference source:Quinta Typesetting: moly Executing: moly
Click "Read the original text" to see more content